Trials / Completed
CompletedNCT00590096
I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,380 (actual)
- Sponsor
- Children's Hospital Medical Center, Cincinnati · Academic / Other
- Sex
- All
- Age
- 2 Weeks
- Healthy volunteers
- Not accepted
Summary
I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors
Detailed description
Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma. Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free I-123-iodide
Conditions
Timeline
- Start date
- 1991-01-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2008-01-10
- Last updated
- 2009-08-25
Source: ClinicalTrials.gov record NCT00590096. Inclusion in this directory is not an endorsement.